Engineered crRNA Drives RPA‐T7‐CRISPR/Cas14a Cascade for Ultrasensitive Detection of ctDNA PIK3CA H1047R
Authors:
Open Access
- 30 August 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 12 (44) , e07126
Abstract
The early detection of circulating tumor DNA (ctDNA) at mutant allele frequencies below 0.1% remains a critical challenge, significantly impeding therapeutic decision‐making. To address this limitation, TIDE‐Cas14a—an innovative CRISPR/Cas14a‐based duplex detection system is developed that integrates recombinase polymerase amplification (RPA) with T7 exonuclease‐mediated strand displacement. By strategically engineering crRNAs with synthetic mismatches, the platform achieves single‐nucleotide resolution, enabling specific discrimination of the PIK3CA H1047R (c.3140A>G) variant from other mutant subtypes and wild‐type sequences at a detection limit of 0.01% with attomolar sensitivity. The system leverages T7 exonuclease's 5′→3′ digestion to convert RPA amplicons into single‐stranded targets, thereby activating Cas14a without requiring thermal cycling. Furthermore, clinical validation using 32 breast cancer patient samples demonstrated that TIDE‐Cas14a achieves 100% sensitivity and specificity, comparable to droplet digital PCR. When deployed on a low‐cost digital microfluidic chip, the assay completes ctDNA profiling within 60 min at 37 °C, effectively bridging the gap between complex laboratory testing and point‐of‐care diagnostics. The work repurposes the CRISPR/Cas system's inherent specificity constraints as a precision oncology tool, establishing a scalable platform for early cancer detection and therapeutic monitoring.Keywords
Funding Information
- National Natural Science Foundation of China (82073410 82272623)
This publication has 74 references indexed in Scilit:
- Deep Learning‐Enhanced Hand‐Driven Microfluidic Chip for Multiplexed Nucleic Acid Detection Based on RPA/CRISPRAdvanced Science, 2025
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwideInternational Journal of Cancer, 2024
- Programmable Multiplexed Nucleic Acid Detection by Harnessing Specificity Defect of CRISPR‐Cas12aAdvanced Science, 2024
- Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerJAMA, 2024
- Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast CancerJAMA Oncology, 2023
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing InterferenceJAMA Oncology, 2021
- Digital CRISPR/Cas‐Assisted Assay for Rapid and Sensitive Detection of SARS‐CoV‐2Advanced Science, 2020
- Monitoring Melanoma Using Circulating Free DNAAmerican Journal of Clinical Dermatology, 2018
- Determining lower limits of detection of digital PCR assays for cancer-related gene mutationsBiomolecular Detection and Quantification, 2014
- Comparison of different methods for generation of single-stranded DNA for SELEX processesAnalytical and Bioanalytical Chemistry, 2012